This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Methods used to judge relevance and validity, and for extracting data
As already reported, parameters came from empirical data when available. No specific details of the methods used to obtain data from other sources were reported, but the reader was referred to the full report (Low et al. 2007 ).
Measure of benefits used in the economic analysis
The measure of benefit was "major outcome averted". A "major outcome" was defined as the occurrence of at least one episode of PID leading to hospital admission, ectopic pregnancy, infertility, or neonatal complications due to chlamydia. Discounting was performed at a rate of 3.5%.
Direct costs
The primary cost and resource use data, including the private costs to patients of participating in the screening programme, were prospectively collected and reported in detail elsewhere (Robinson et al. 2007 , see 'Other Publications of Related Interest' below for bibliographic details). The costs of running the chlamydia screening studies project, including laboratory staff and tests, treatment and partner notification, were used as a proxy for NHS costs. The unit costs were reported clearly. The costs were converted to 2005 prices using the combined hospital and community index. Discounting was performed at a rate of 3.5%.
Statistical analysis of costs
The results were mainly reported as deterministic data.
Indirect Costs
The patient's private costs of screening were included when reporting a societal perspective, but they were not reported in detail.
Currency
Pounds sterling ().
Sensitivity analysis
Different one-way or scenario sensitivity analyses were performed. Such analyses investigated the private cost to individuals, variations in response rates and screening intervals, the discount rate, the incidence of PID (including a scenario of high uptake and high incidence of PID, and variations in the costs of PID and infertility. The values used were justified.
